Hong Kong's IPO Market Just Ranked First Globally — What Retail Investors Should Know

Hong Kong raised roughly HK$103 billion through IPOs in the first quarter, putting it at the top of global fundraising rankings for the period. That figure represents close to a fivefold increase from Q1 last year. The pipeline is deep -- more than 500 companies are reportedly waiting to list on the HKEX -- and PwC projects the full year could reach HK$320-350 billion in total proceeds.

But the headline numbers obscure some shifts that matter more to retail investors than the ranking itself. Retail allocation has dropped significantly, new economy listings under Chapter 18C and 18A rules are reshaping the composition of the market, and tariff uncertainty adds a layer of macro risk that did not exist in the previous cycle.

Table of Contents

• How Much Did Hong Kong Raise in Q1 IPOs?
• Q1 vs Q1 2025 Comparison
• Which Companies Listed in Q1?
• What Sectors Are Driving the Pipeline?
• What Does Reduced Retail Allocation Mean for Small Investors?
• How Real Is the Tariff Risk?
• How We Researched This
• Frequently Asked Questions

How Much Did Hong Kong Raise in Q1 IPOs?

The HK$103 billion figure covers all IPO proceeds on the HKEX main board and GEM board from January through March. For context, the same quarter last year brought in approximately HK$21 billion -- meaning this year's Q1 was about 4.9 times larger. That jump is partly base-effect (Q1 last year was unusually quiet), partly a genuine acceleration in listing activity driven by Chinese companies choosing Hong Kong over US exchanges.

Hong Kong overtook both the New York Stock Exchange and Nasdaq in Q1 fundraising volume. The last time Hong Kong held the global top spot for a full quarter was during the wave of Chinese mega-listings in the early 2020s. Whether it holds this position through Q2 depends on the pipeline converting into completed deals -- and on macro conditions not deteriorating sharply.

The broader economic backdrop in Hong Kong has been supportive. Exports grew around 30% year-over-year, and the unemployment rate fell to 3.8%. These are not IPO-specific indicators, but they create a macro environment where institutional investors are more willing to participate in new offerings, which keeps deal flow moving.

Q1 IPO Market: This Year vs Last Year

Metric	Q1 2026	Q1 2025	Change
Total IPO proceeds	HK$103B	~HK$21B	+~390%
Global ranking	#1	Outside top 3	—
Pipeline companies	500+	~200	+150%
Retail allocation (typical)	~10%	Up to 50%	Sharply reduced
Key sectors	Consumer, AI, biotech	Tech, property	Sector rotation
Full-year forecast (PwC)	HK$320-350B	~HK$100B (actual)	3x+ projected

Which Companies Listed in Q1?

Two listings dominated the quarter's activity:

Muyuan Foods (牧原食品)

China's largest hog producer by volume. Muyuan's Hong Kong listing raised a significant portion of the quarter's total proceeds. The company already trades in Shenzhen, so the HK listing is a secondary listing designed to attract international capital and provide a hedge against domestic market volatility. For investors, Muyuan is a proxy for Chinese consumer staples demand -- less exciting than AI chips but with actual earnings and dividends.

Dongpeng Beverage (东鹏饮料)

Dongpeng makes energy drinks. Its flagship product competes with Red Bull in the Chinese market. Similar to Muyuan, this is a dual-listing -- the company already has a Shenzhen-listed stock. The Hong Kong listing gives it access to the southbound Stock Connect flow and international institutional investors. Revenue growth has been strong, driven by distribution expansion into lower-tier Chinese cities.

The broader pattern

Q1 was dominated by large, established Chinese companies doing secondary listings in Hong Kong rather than startups raising their first round of public capital. This pattern inflates the total proceeds figure but may not translate into the kind of high-volatility, high-upside IPO opportunities that retail subscribers tend to chase. The more speculative listings -- Chapter 18C tech companies and 18A biotech -- are concentrated later in the pipeline.

What Sectors Are Driving the Pipeline?

Three categories account for most of the 500+ company pipeline:

Chapter 18C specialist technology companies. These are innovative tech firms that may not meet traditional listing profitability requirements. The 18C framework, introduced to attract AI, semiconductor, and deep-tech companies, has become a significant pipeline driver. Several AI infrastructure companies are in various stages of the application process, buoyed by the current wave of enthusiasm around Chinese AI models like DeepSeek and Qwen.

Chapter 18A biotech. The biotech pipeline remains active, though investor appetite has cooled compared to the frenzy of 2021-2022. Companies listing under 18A rules are pre-revenue, which means they carry higher risk. Several oncology and gene therapy companies are expected to list in Q2-Q3, but first-day premiums for biotech IPOs have been inconsistent.

Consumer and industrial mega-caps. The Muyuan and Dongpeng model -- large mainland Chinese companies doing secondary listings -- is likely to continue. These are lower-volatility offerings that appeal to institutional investors but offer less upside for retail subscribers hoping for first-day pops.

For retail investors, the distinction matters. A consumer staples secondary listing might open flat and trade sideways for months. A 18C semiconductor IPO might open +50% or -20%. Understanding which category you are subscribing to changes the risk-reward profile entirely.

What Does Reduced Retail Allocation Mean for Small Investors?

This is the change that affects individual investors most directly. In previous IPO cycles, retail investors could receive up to 50% of an IPO's total shares through the public offer tranche, especially when clawback mechanisms triggered due to high retail demand. That structure has shifted.

For many recent listings, the retail allocation has been around 10% of total shares, with the remaining 90% going to institutional and cornerstone investors. The reasons are partly structural (issuers prefer the price stability that comes with institutional placement) and partly regulatory (the HKEX has been adjusting rules around public offer sizes).

Practical impact:

• Lower allotment probability. If 10% of shares go to retail but retail demand is 50x oversubscribed, your chance of receiving any shares drops significantly. For popular IPOs, minimum-lot applicants might see allotment rates of 5-8%.
• Margin financing becomes less efficient. The math on 10x margin for IPO subscription works when you have a reasonable probability of receiving shares. When allotment rates drop below 10%, you are paying margin interest on nine out of ten attempts that result in zero allocation.
• Multi-account strategy has diminishing returns. Using multiple broker accounts to increase your chances is standard practice, but with lower retail tranches, even multiple applications may not overcome the math. Read our multi-account strategy guide for current calculations.

None of this means retail investors should stop participating. It means expectations need to adjust. The days of reliably getting allocated shares in every hot IPO through a single minimum-lot application are probably behind us.

How Real Is the Tariff Risk?

The tariff situation is the one variable that could disrupt the entire IPO pipeline. US-China tariff escalation has the potential to dampen investor sentiment, slow cross-border capital flows, and push companies to delay listings until conditions stabilize.

What we know: As of early April, tariff rhetoric has intensified but the direct impact on Hong Kong's market has been contained. The Hang Seng Index has shown resilience, and the Q1 fundraising numbers speak for themselves. HK exports grew around 30% YoY, suggesting trade activity has not collapsed.

What could go wrong: A significant tariff escalation -- particularly targeting Chinese technology companies or semiconductor supply chains -- could freeze the 18C pipeline overnight. Companies will not list into hostile market conditions, and institutional investors will pull back from new commitments. The AI-related listings are most vulnerable here, since many of these companies have US technology dependencies (design tools, manufacturing equipment, customer relationships) that could be disrupted by trade policy changes.

The honest assessment: Nobody knows how the tariff situation will evolve. The pipeline is strong, the economic data is supportive, and Q1 results demonstrate genuine momentum. But any investment thesis that assumes smooth sailing for the rest of the year is ignoring a real and unpredictable risk factor. If you are sizing your IPO participation, this uncertainty is a reason to keep position sizes modest rather than betting aggressively on every listing.

How We Researched This

This analysis draws on HKEX official listing statistics, PwC's Q1 Hong Kong IPO market report, Securities and Futures Commission filings, and macroeconomic data from the Hong Kong Census and Statistics Department. IPO proceeds figures reference HKEX official announcements. Pipeline estimates (500+ companies) are based on active listing applications reported by the HKEX as of March. PwC's full-year forecast (HK$320-350 billion) is cited directly from their published outlook. We do not receive compensation from any issuer, underwriter, or broker mentioned in this article.

Frequently Asked Questions

Did Hong Kong really rank first globally for IPOs in Q1?

Yes. Hong Kong raised approximately HK$103 billion in IPO proceeds during Q1, which placed it ahead of the NYSE, Nasdaq, and all other global exchanges for the quarter. This was driven primarily by large secondary listings of established Chinese companies. The ranking is based on total proceeds rather than number of listings -- Hong Kong did not necessarily have the most IPOs by count, but raised the most capital.

How does the reduced retail allocation affect my IPO strategy?

With retail allocation at roughly 10% of total IPO shares (down from up to 50% in past cycles), your probability of receiving shares in popular offerings is significantly lower. Allotment rates for minimum-lot applications in oversubscribed IPOs may fall to 5-8%. This makes selective participation more important -- focus on IPOs with strong fundamentals rather than subscribing to everything. Consider using multiple broker accounts and margin financing strategically, but adjust your expectations for allotment rates. For detailed broker comparisons, see our broker comparison guide.

What are Chapter 18C and 18A listings?

Chapter 18C is the HKEX listing framework for specialist technology companies -- firms in AI, semiconductors, quantum computing, and similar fields that may not meet traditional revenue or profitability requirements. Chapter 18A serves a similar function for pre-revenue biotech companies. Both frameworks allow earlier-stage companies to access public markets, which means higher growth potential but also higher risk for investors. A substantial portion of the current 500+ company pipeline consists of 18C and 18A applicants.

Should I worry about tariff risk when subscribing to IPOs?

Tariff uncertainty is a genuine risk factor but should not paralyze decision-making. The practical approach is to keep individual IPO positions modest (no more than you can afford to lose entirely), avoid excessive margin on companies with direct US-China trade exposure, and watch for headline risk around specific sectors. Companies in consumer staples (like Muyuan Foods) have less tariff exposure than semiconductor or AI companies listing under Chapter 18C rules.

What brokers support Hong Kong IPO subscription?

Several brokers licensed in Hong Kong support retail IPO subscription. moomoo offers 0-commission IPO subscription with up to 10x margin financing. Tiger Brokers and IBKR also support HK IPO applications. For a detailed comparison of features and fees, see our best broker for HK IPO beginners guide and our IPO margin financing breakdown.

Related Reading

• Hong Kong IPO Pipeline for Q2 — What Retail Investors Should Watch -- forward-looking analysis of Q2 pipeline and key listings
• Best Broker for HK IPO Beginners -- step-by-step guide to opening an account and subscribing
• HK IPO Margin Financing Guide -- how margin works for IPO subscription, costs, and risks
• Hong Kong Stock Broker Comparison -- side-by-side broker comparison for HK stock trading

Disclaimer

This article is for educational and informational purposes only and does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security. IPO investing carries significant risk including the possibility of losing your entire investment. Past IPO performance does not guarantee future results. Pipeline estimates and forecasts are based on publicly available information and may change without notice. Always conduct your own due diligence and consult a licensed financial advisor before making investment decisions.